Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is lymphocyte activation gene-3 (LAG3), which suppresses the antitumor immune response. Moffitt Cancer Center researchers have made an important discovery about LAG3, revealing how it interacts with other proteins to control immune activity. Their study, published in Nature Communications, could lead to better cancer treatments by enhancing the effectiveness of immune checkpoint inhibitors.
This article was originally published on MedicalXpress.com
